Researchers To Tackle New Macular Degeneration Target Using Antisense
This article was originally published in Start Up
A research team has identified a way to treat the dry form of advanced age-related macular degeneration, for which no therapy exists to halt the associated vision loss. The team expects to start clinical testing of an antisense compound to address the problem, an accumulation of a type of RNA, by the end of the year.
You may also be interested in...
The founders of PanOptica are inspired by the big impact VEGF-inhibitors originally developed for cancer are having on the ophthalmic market. So much so, that they company aims to search out compounds from other disease areas such as cancer, diabetes and other metabolic disorders, and find those likely to have potential for serious eye disorders.
Dicerna Pharmaceuticals hopes to elude the IP fortresses of Alnylam and Merck with a license to RNA interference IP out of City of Hope's Beckman Research Institute. If successful, this adjacent doorway into RNAi could create a new option for those pharma companies that have thus far stayed on the sidelines of the RNAi game.
Merck's takeout of Sirna gives a boost to platform biotech investors and has allowed Merck to stake an expansive claim in RNAi. The deal caps a massive turnaround for Sirna--previously Ribozyme Pharmaceuticals--and rewards the investors who took an early chance on RNAi therapies. The move should pay off handsomely for Merck, now the leader in RNAi, provided the technology turns out to be the next Antibodies, not the next Antisense.